- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:physicians:emergency [02.08.2017] – [Notice for emergency medical personnel] sallieq | home:physicians:emergency [09.16.2017] – [Notice for emergency medical personnel] sallieq | ||
|---|---|---|---|
| Line 25: | Line 25: | ||
| If B/P is extremely low (mean arterial pressure <55), continue Benicar as above and increase fluid volume with 0.9 NS or packed red cells. | If B/P is extremely low (mean arterial pressure <55), continue Benicar as above and increase fluid volume with 0.9 NS or packed red cells. | ||
| + | |||
| + | |||
| + | Ceftin (Cefuroxime, | ||
| + | |||
| + | Biaxin (Clarithromycin) has been reported with similar good results, but may not be suitable for a patient with a heart condition. | ||
| + | |||
| + | Cephalosporins **may** be tolerated, Claforin is usually OK. | ||
| + | |||
| + | Biaxin and Ceftin are actually preferred to Fluoroquinolones although they may be well tolerated, since instances of tendon damage have been reported, and more recently they have been linked to a higher risk of retinal detachment. **The patient should be advised of the FDA black-box warnings.** | ||
| Line 32: | Line 41: | ||
| * tetracyclines | * tetracyclines | ||
| * sulfa drugs | * sulfa drugs | ||
| - | |||
| - | |||
| - | |||
| - | Cephalosporins **may** be tolerated, Claforin is usually OK. | ||
| - | |||
| - | The macrolide Biaxin is usually OK, as is Ceftin. | ||
| - | |||
| - | Fluoroquinolone antibiotics may be well tolerated, although instances of tendon damage have been reported, and more recently these have been linked to a higher risk of retinal detachment. **The patient should be advised of the FDA black-box warnings.** | ||
| Line 45: | Line 46: | ||
| **Do not give** corticosteroids in any form or by any route (injected, inhaled, oral or IV) as they | **Do not give** corticosteroids in any form or by any route (injected, inhaled, oral or IV) as they | ||
| will lead to metabolic instability. | will lead to metabolic instability. | ||
| + | |||
| + | Do not give Telmisartan, | ||
| **Do not give nimesulide** (Aulin / Mesulid / Nimed). | **Do not give nimesulide** (Aulin / Mesulid / Nimed). | ||
home/physicians/emergency.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.